Dear Friends, Dear Colleagues,

The annual “LabEx MAbImprove industrial workshops” are primarily intended to provide scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry. In 2014, they are organised by the “LabEx MAbImprove industrial committee”, in partnership with Transfert-LR, the Languedoc-Roussillon regional innovation agency and Eurobiomed, the Mediterranean Biocluster including the “Provence Alpes Côte d’Azur” and “Languedoc-Roussillon” regions.

The 2014 edition, second in the series of “LabEx MAbImprove industrial workshops” is dedicated to the question of the antibody dose.
How to choose, during Phase I, the dose of a drug that is not directly cytotoxic? How to define the "optimal" dose, the more effective one? What are the most effective techniques for antibodies monitoring and modeling calculation methods in humans? How to adapt a dose optimized for a monotherapy when several antibodies are associated? Can animal models help us to answer these questions? If so, which ones (primates, GM models, ...)? What is the impact of a change in the dose on antibody immunogenicity, efficacy and cost of treatment? ...

As in the first edition of these industrial workshop devoted to biosimilar antibodies, the theme of the dose thus raises medical, economic and ethical scientific issues. We believe it is important for all players in the field (academia, industry, regulatory agencies, pharmacists, health authorities, health insurance personnel) to exchange on this subject. This is the objective of this scientific symposium. The topics and speakers were carefully selected; the report of the meeting will be published in the international journal Mabs.

We look forward to welcoming and hosting you in Montpellier in July 3rd 2014, and sincerely hope that you will join us to make this endeavour a success.

Pr Hervé Watier

Dr André Pèlegrin